BHC:NYE-Bausch Health Companies Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NYE

Last Closing Price

USD 30.30

Change

+0.04 (+0.13)%

Market Cap

USD 10.73B

Volume

1.60M

Average Target Price

USD 36.51 (+20.48%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-15 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ZTS Zoetis Inc

+2.37 (+1.45%)

USD77.46B 47.68 29.87
TAK Takeda Pharmaceutical Company ..

+0.14 (+0.82%)

USD53.74B 32.50 0.10
CTLT Catalent, Inc

+1.08 (+0.98%)

USD18.71B 60.89 27.78
ELAN Elanco Animal Health Incorpora..

+0.62 (+2.10%)

USD13.90B 144.89 153.79
TEVA Teva Pharmaceutical Industries..

-0.05 (-0.46%)

USD12.00B 872.00 16.02
RDY Dr. Reddy's Laboratories Limit..

+1.05 (+1.66%)

USD10.64B 37.01 0.26
PRGO Perrigo Company plc

+0.79 (+1.96%)

USD5.39B 24.33 23.14
EBS Emergent BioSolutions Inc

N/A

USD4.00B 13.16 7.91
TARO Taro Pharmaceutical Industries..

+1.65 (+2.27%)

USD2.79B 10.60 4.58
ACB Aurora Cannabis Inc

-0.19 (-2.38%)

USD1.57B 43.15 N/A

ETFs Containing BHC

Symbol Name Weight Mer Price(Change) Market Cap
BSJL Invesco BulletShares 2021.. 0.00 % 0.42 %

+0.02 (+0.07%)

USD0.74B
SHYL Xtrackers Short Duration .. 0.00 % 0.20 %

+0.12 (+0.25%)

USD0.04B
SYBK:F SPDR Bloomberg Barclays 0.. 0.00 % 0.40 %

+0.10 (+0.26%)

USD0.16B
SYBJ:F SPDR Bloomberg Barclays E.. 0.00 % 0.40 %

+0.05 (+0.08%)

USD0.83B
JNKE:PA SPDR Bloomberg Barclays E.. 0.00 % 0.40 %

+0.06 (+0.10%)

USD0.97B
SJNK:LSE SPDR Bloomberg Barclays 0.. 0.00 % 0.40 %

+0.11 (+0.23%)

USD0.15B
JNKS:LSE SPDR Bloomberg Barclays 0.. 0.00 % 0.40 %

+0.07 (+0.21%)

USD0.13B
HYGV FlexShares High Yield Val.. 0.00 % 0.37 %

+0.17 (+0.35%)

USD0.21B
HYUP Xtrackers High Beta High .. 0.00 % 0.20 %

+0.18 (+0.36%)

USD9.62M
GHYB Goldman Sachs Access High.. 0.00 % 0.34 %

+0.19 (+0.37%)

USD0.19B
CJNK SPDR ICE BofAML Broad Hig.. 0.00 % 0.15 %

N/A

USD0.07B
BSJP Invesco BulletShares 2025.. 0.00 % 0.42 %

+0.05 (+0.18%)

USD0.24B
HYLB Xtrackers USD High Yield .. 0.00 % 0.15 %

+0.13 (+0.32%)

USD6.76B
SJB ProShares Short High Yiel.. 0.00 % 0.95 %

-0.08 (-0.45%)

USD0.06B
RFUN RiverFront Dynamic Uncons.. 0.00 % 0.52 %

+0.05 (+0.19%)

USD0.01B
JNK SPDR Bloomberg Barclays H.. 0.00 % 0.40 %

+0.45 (+0.41%)

USD9.80B
HYLS First Trust Tactical High.. 0.00 % 1.01 %

+0.10 (+0.21%)

USD2.27B
HYG iShares iBoxx $ High Yiel.. 0.00 % 0.49 %

+0.35 (+0.40%)

USD22.02B
SYBK:XETRA SPDR Bloomberg Barclays 0.. 0.00 % 0.40 %

+0.22 (+0.58%)

USD0.15B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 45.67% 78% C+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.67% 78% C+ 93% A
Trailing 12 Months  
Capital Gain 79.08% 61% D- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 79.08% 61% D- 69% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.86% 44% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.86% 44% F 19% F
Risk Return Profile  
Volatility (Standard Deviation) 28.56% 72% C- 32% F
Risk Adjusted Return -6.51% 50% F 20% F
Market Capitalization 10.73B 72% C- 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 20.46 11% F 5% F
Price / Cash Flow Ratio 9.66 28% F 46% F
EV/EBITDA 14.12 54% F 51% F
Management Effectiveness  
Return on Equity -64.22% 17% F 7% F
Return on Invested Capital 6.57% 56% F 62% D-
Return on Assets 2.56% 61% D- 58% F
Debt to Equity Ratio 4,471.96% 7% F 0% N/A
Technical Ratios  
Short Ratio 2.27 61% D- 41% F
Short Percent 4.50% 54% F 47% F
Beta 1.73 28% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector